

## 2023 Summit and Summit KOL EASL Abstracts

<b><u>Abstract Lead Author</u></b>	<b><u>Summit Contributor</u></b>	<b><u>Page</u></b>	<b><u>Title</u></b>
Stephen Harrison	Jorn Schattenberg, Mazen Nouredin, Naim Alkhouri	S1	Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis
Stephen Harrison	Rebecca Taub, Dominic Labriola, Yayun Ren, Elaine Chng, Dean Tai	S112	Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo
Mary Rinella	Rohit Loomba, Kris Kowdely, Quentin Anstee, Mazen Nouredin, Zobair Younossi, Naim Alkhouri, Jerome Boursier, Stephen Harrison, Thomas Capozza, Jing Li, Christopher Gasink	S118	Evaluation of non-invasive tests to identify precirrhotic fibrosis due to NASH in patients screened for the phase 3 REGENERATE and REVERSE studies of obeticholic acid
Rohit Loomba	Arun Sanyal, Kris Kowdely, Deepak Bhatt, Naim Alkhouri, Juan P Frias, Pierre Beossa, Stephen Harrison, Don Lazas, Robert Barish, Millie Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia Hartsfield, Hank Mansbach, Maya Margalit, Manal Abdelmalek,	S14	Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
Mazen Nouredin	Julie Dubourg, Stephen Harrison, Sophie Jeannin Megnien, Vlad Ratziu, Michael Charlton, Naim Alkhouri, Jorn Schattenberg	S31	Performance of vibration controlled transient elastography and related scores to identify at-risk non-alcoholic steatohepatitis patients: combined data from multiple trials including more than 5,000 patients ( in collaboration with NAIL-NIT consortium)
Naim Alkhouri	Julie Dubourg, Stephen Harrison, Michael Charlton, Vlad Ratziu, Jorn	S31	Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple

	Schattenberg, Sophie Jeannin Megnien, Mazen Noureddin,		therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Stephen Harrison	Hanna Pulaski, Marlena Vitali, Laryssa Manigat, Stephanie Kaufman, Hypatia Hou, Susan Madasu, Sara Hoffman, Adam Stanford-Moore, Robert Egger, Janani Iyer, Jonathan Glickman, Murray Resnick, Neel Patel, Cristin Taylor, Shraddha Mehta, Robert Myers Chuhan Chung, Scott Patterson, Anne- Sophie Sejling, Anne Minnich, Vipul Baxi, Mani Subramanian, Arun Sanyal, Quentin Anstee, Rohit Loomba, Vlad Ratziu, Katy Wack	S32	Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology
Rohit Loomba	Marie O'Farrell, Katharine Grimmer, Alitheia Zetter, Wen- Wei Tsai, George Kemble, Eduardo Bruno Martins, Stephen Harrison	S53	Multicenter, Randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, deifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASINATE-2 Phase 2B trial
Jorn Schattenberg	Julie Dubourg, Mazen Noureddin, Naim Alkhouri, Vlad Ratziu, Michael Charlton, Sophie Jeannin Megnien, Stephen Harrison	S604	Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trails including more than 5000 patients ( in collaboration with NAIL-NIT consortium)
Vlad Ratziu	Javier Ampuero, Jerome Boursier, Stergios Kechagias, Salvatore Petta, Hannes Hagstrom, Jorn Schattenberg, Lisa Belin, Stacy	S607	Histological classifications versus liver-related events: results from the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study

	Cyrille, Fredric Charlotte, Leila Kara, Pierre Bedossa		
Mazen Nouredin	Julie Dubourg, Jorn Schattenberg, Michael Charlton, Stephen Harrison, Naim Alkhouri, Sophie Jeannin Megnier, Vlad Ratziu,	S619	The impact of glycemic control on progressive forms of non-alcoholic fatty liver disease: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Stephen Harrison	Julie Dubourg, Sophie Jeannin Megnier, Jorn Schattenberg, Vlad Ratziu, Michael Charlton, Naim Alkhouri, Mazen Nouredin	S619	Glycated hemoglobin as an independent predictor of hepatocyte ballooning in non- alcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Sophie Jeannin Megnier	Julie Dubourg, Jorn Schattenberg, Vlad Ratziu, Stephen Harrison, Mazen Nouredin, Naim Alkhouri, Michael Charlton	S643	Comparison of non-alcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Rohit Loomba	Quentin Anstee, Stephen Harrison, Naim Alkhouri, Mary Rinella, Thomas Capozza, Christopher Gasink, Amarita Randhawa	S647	Significant dose- dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre- cirrhotic fibrosis due to non-alcoholic steatohepatitis
Eduardo Vilar Gomez	Deven Parmar, Niharika Samala, Raj Vuppalanchi, Samer Gawrieh, Oscar Cummings, Stephen Harrison, Rohit Loomba, Naga Chalasani	S649	A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes
Quentin Anstee	Philippe Huot- Marchand, Lucile Dzen, Jean-Louis Junien, Pierre Broqua, Sven Francque, Manal Abdelmalek, Michael Cooreman, Stephan Harrison	S651	Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH

Vlad Ratziu	Rambabu Surabattula, Elisbetta Bugianesi, Jorn Schattenberg, Maharajah Ponnaiah, Chiara Rosso, Angelo Armandi, Sudha Myneni, Raluca Pais, Leila Kara Detlef Schuppan	S652	Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohort
Stephen Harrison	Nadege Gunn, Guy Neff, Abbey Flyer, Alexander Liberman, Leigh MacConell	S653	Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus
Naim Alkhouri	Julie Dubourg, Stephen Harrison, Mazen Nouredin, Michael Charlton, Vlad Ratziu, Sophie Jeannin Megnein, Jorn Schattenberg	S655	Performance of non-invasive test as exclusion criteria for cirrhosis in trials targeting at-risk non-alcoholic steatohepatitis: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Mazen Nouredin	Devon Y. Chang, Emily Truong, Ju Dong Yang, Naim Alkhouri, Stephen Harrison	S659	Machine Learning with routine laboratory test and clinical features performs similar to current NAFLD clinical pathways
Vlad Ratziu	Stephen Harrison, Yacine Hajji, Jeremy Magnannensi, Stephanie Petit, Zouher Majd, Christian, Rosenquist, Dean Hum, Bart Staels, Quentin Anstee, Arun Sanyal,	S668	NIS2+TM as a screening tool for optimizing patient selection in non-alcoholic steatohepatitis therapeutic trials
Rohit Loomba	Mazen Nouredin, Rebecca Taub, Naim Alkhouri, Kris Kowdely, Greg Everson, Stephen Harrison	S684	Imaging and biomarker thresholds to accurately diagnose NASH cirrhosis in a 180 patient biopsy confirmed cohort

Pratik Mistry	Adam Stanford-Moore, Robert Egger, Jonathan Glickman, Brian Baker, Nidhi Chandra, Dinkar Juyal, Archit Khosla, Michael Drage, Murray Resnick, Katy Wack, Jim Hennan, Rohit Loomba, Stephen Harrison, Rebecca Taub, Janani Lyer	S790	Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology
Jorn Schattenberg	Juan P Frias, Guy Neff, Gary Abrams, Kathryn Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammad Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Reshma Shringarpure, Dorren Chan, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Stephen Harrison	S808	Non-invasive test of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2- F3 NASH patients: secondary analysis of Ph2b HARMONY study
Naim Alkhouri	Yongheng Liu, Nain Liang, Peibin Zhai, Sandra Wu, Xin Zhou, Michael Xu, Que Liu, Stephen Harrison	S812	HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study
Naim Alkhouri	Rebecca Taub, Guy Neff, Kathryn Jean Lucas, Dominic Labriola, Sam Moussa, Mustafa Bashir, Stephen Harrison	S813	Resmetirom improves the lipid/lipoprotein profile in patients with non-alcoholic fatty liver disease
Stephen Harrison	Rebecca Taub, Guy Neff, Mustafa Bashir, Dominic Labriolo, Sam Moussa, Naim Alkhouri, Kathryn Jean Lucas	S815	Resmetirom helps regulate thyroid hormone levels within the liver in patients with non-alcoholic fatty liver disease

Cynthia Behling	Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Stephen Harrison	S820	Characterization of the patterns of resolution of histopathology after efruxifermin treatment of patients with NASH fibrosis (F2/3) for 24 weeks
Jorn Schattenberg	Yayun Ren, Dean Tai, Elaine Chng, Stephen Harrison	S824	Hepatic fat and liver volume reduction-impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis
Quentin Anstee	Jeremy Magnanensi, Yacine Hajji, Alexandra Caron, Zouher Majd, Chistian Rosenquist, Dean Hum, Bart Staels, Margery A. Connelly, Rohit Loomba, Stephen Harrison, Vlad Ratziu, Arun Sanyal		Impact of age as a confounding factor on non-invasive blood-based test for the evaluation of non-alcoholic fatty liver disease: comparing NIS2+TM to established test
Stephen Harrison	Shaheen Tomah, John Suschak, Scot Roberts, Jay Yang, Liang He, Bertrand Georges, Lakisha Rodwell-Green, Randy Brown, M. Scott Harris, Sarah Browne		Pemvidutide, a glp-1/ glucagon dual receptor agonist, significantly reduces liver fat, fibro- inflammation, and body weight in patients with non- alcoholic fatty liver disease: a 24-week multicenter, randomized, doble-blind, placebo-controlled trial

